Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG)

Annales d'Endocrinologie

Volumn 67, Issue 2, 2006, Pages 139-141

  Hofbauer, L C ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; GLUCOCORTICOID; HYBRID PROTEIN; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; UNCLASSIFIED DRUG;

BONE DISEASE; CELL SURFACE; CLINICAL TRIAL; CYTOLOGY; HUMAN; HYPERCALCEMIA; IMMUNOREACTIVITY; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 33646423314     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4266(06)72569-0     Document Type: Article

References (24)

1. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001 ; 16 : 348-60.
2. Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004 ; 19 : 1059-66.
3. Body JJ, Greipp P, Coleman RE et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003 ; 97(3 Suppl) : 887-92.
4. Croucher PI, Shipman CM, Lippitt J et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001 ; 98 : 3534-40.
5. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999 ; 13 : 2412-24.
6. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003 ; 111 : 1221-30.
7. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001 ; 98 : 3527-33.
8. Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999 ; 140 : 4382-9.
9. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004 ; 292 : 490-5.
10. Honore P, Luger NM, Sabino MA et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med 2000 ; 5 : 521-8.
11. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci (USA) 1999 ; 96 : 3540-5.
12. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 ; 397 : 315-23.
13. Kong YY, Feige U, Sarosi I et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999 ; 402 : 304-9.
14. Lacey DI, Timms E, Tan HL et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 ; 93 : 165-76.
15. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K. Receptor activator of nuclear factor κB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001 ; 61 : 1637-44.
16. Min H, Morony S, Sarosi I et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000 ; 192 : 463-74.
17. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001 ; 61 : 2572-8.
18. Pearse RN, Sordillo EM, Yaccoby S et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to stimulate bone destruction and promote tumor progression. Proc Natl Acad Sci (USA) 2001 ; 98 : 11581-6.
19. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005 ; 90 : 6323-31.
20. Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003 ; 101 : 2094-8.
21. Simonet WS, Lacey DI, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 ; 89 : 309-19.
22. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000 ; 289 : 1504-8.
23. Teng Y-TA, Nguyen H, Gao X et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000 ; 106 : R59-67.
24. Zhang J, Dai J, Qi Y et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001 ; 107 : 1235-44.